Road, ORMOND” where
I worked doing general practice sessions for most of this year.
An offer from Parke-
Davis “Neurology Care” to send me some “Parke DavisEpilepsy Education” regarding epileptic patients’ fitness to drive with a
out glossy enclosure titled “epilepsy, driving and safety”.
An offer from Schering to send me “excellent resources on treatment andmanagement along with practical education and support services”, should Ihave a particular interest in Multiple Sclerosis (MS) and specifically if I am “
general practitioner out of every twenty managing a Betaferon patient”.
A separate plastic envelope containing the “MIMS Supplement No.3 1999Annual” introducing “Celebrex” for arthritis treatment and Micardis/Pritor, a“new angiotensin II receptor
antagonist for mild to moderate hypertension”,enclosed with a A5 sized booklet described as a “MIMS Product Review”introducing “Clopidogrel: Plavix” credited to “Dr Greg Conner, Vascular
Physician, Darlinghurst, NSW; Professor Geoffrey Donnan, Department of
Neurology, Austin Hospital, Heidelberg, Victoria; and “Dr Andrew Taylor, HeartCentre, Alfred Hospital, Prahran Victoria”.
The last of these five items contained an A5 sized glossycovering letter which reads as follows:
We are pleased to announce an important advance for yourpatients at risk of myocardial infarction (MI) and ischaemicstroke and vascular death: New PLAVIX®.